Abbvie Inc.

Abbvic Inc.

Abbvie Ireland Unlimited Company

Cheri E Klein

Sandeep Dutta

Walid M Awni

Sven Mensing

Daniel E Cohen

Barry M Bernstein

Thomas J Podsadecki

Rajeev M Menon

Scott C Brun

Emily O Dumas

Amit Khatri

Juki Wing-Keung Ng

Sandra L Goss

Ahmed Salem

John K Morris

Joerg Rosenberg

Laman L Alani

Gunther Berndl

Bernd Liepold

Soumojeet Ghosh

Yihong Qiu

Joerg Breitenbach

Katja Fastnacht

Tina Jung

Wolfgang Roth

Yan Cai

The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.

Methods of administering elagolix

Methods of adminstering elagolix

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

Methods for treating HCV

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

The present invention relates to SRSR solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing the dosage forms, and methods for providing therapeutic agents to patients in need of treatment.

Sustained release formulations of opioid and nonopioid analgesics

Growing community of inventors

Northbrook, IL, United States of America

Cheri E Klein